GLP1R and type 2 diabetes mellitus: A large cohort study that included 50,000 type 2 diabetes pregnancies across six countries (USA, Finland, Iceland, Norway, Sweden and Israel) found no strong evidence for increased rates of major congenital anomaly, or of cardiac malformations, associated with use of GLP-1 receptor agonists compared with insulin therapy [50].